AR046222A1 - PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION INCLUDING APLINDORE AND ITS DERIVATIVES - Google Patents
PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION INCLUDING APLINDORE AND ITS DERIVATIVESInfo
- Publication number
- AR046222A1 AR046222A1 ARP040103986A ARP040103986A AR046222A1 AR 046222 A1 AR046222 A1 AR 046222A1 AR P040103986 A ARP040103986 A AR P040103986A AR P040103986 A ARP040103986 A AR P040103986A AR 046222 A1 AR046222 A1 AR 046222A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- defined above
- hydrogen
- controlled release
- Prior art date
Links
- DYJIKHYBKVODAC-ZDUSSCGKSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one Chemical compound C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 DYJIKHYBKVODAC-ZDUSSCGKSA-N 0.000 title 1
- 229950001748 aplindore Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 238000013270 controlled release Methods 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 abstract 1
- CJRPBMIZIBLPDX-UHFFFAOYSA-N 1h-imidazole;1h-indazole Chemical compound C1=CNC=N1.C1=CC=C2C=NNC2=C1 CJRPBMIZIBLPDX-UHFFFAOYSA-N 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- -1 bencisoxazole Chemical compound 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicación 1: Una formulación de dosis de liberación controlada, caracterizada porque comprende un compuesto de la fórmula (1), en la cual: R1y R2 son, independientemente, hidrógeno, alquilo C1-6, fenilo o bencilo; o R1 y R2, tomados en conjunto, son bencilideno opcionalmente sustituido con R3 como se define más adelante o alquilideno de hasta 6 átomos de carbono; o R1 y R2, tomados en conjunto con el átomo de carbono al cual están unidos, forman un residuo carbonilo o un grupo cicloalquilo que tiene hasta 6 átomos de carbono; R3 es hidrógeno, hidroxi, halógeno, trifluorometilo, trifluorometoxi, alquilo C1-6, alcoxi C1-6, arilalcoxi C7-12, alcanoiloxi C2-6, amino, mono- o di-alquilamino en el cual cada grupo alquilo C1-6, alcanamido C2-6 o alcanosulfonamido C1-6; R4 es hidrógeno o alquilo C1-6; n es uno de los números enteros 0, 1, 2, 3, 4, 5, ó 6; Z es hidrógeno, hidroxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, cicloalquilo C3-8, alquilo policíclico C7-15, fenilo opcionalmente sustituido con R3 como se ha definido antes, fenoxi, opcionalmente sustituido con R3 como se ha definido antes, naftilo opcionalmente sustituido con R3 como se ha definido antes o naftiloxi opcionalmente sustituido con R3 como se ha definido antes, heteroarilo o heteroariloxi, en donde el anillo heterocíclico del grupo heteroarilo o heteroariloxi es seleccionado de tiofeno, furano, piridina, pirazina, pirimidina, indol, indazol imidazol, cromano, cumarina, carboestirilo, quinolina, bencisoxazol, benzoxazol, pirazol, pirrol, tiazol, oxazol, o isoxazol y el anillo heterocíclico está opcionalmente sustituido por R3 como se ha definido antes; o una sal farmacéuticamente aceptable de lo mismo. Reivindicación 22: Un método de tratamiento para un desorden del sistema dopaminérgico, caracterizado porque comprende administrar a un paciente que necesita de dicho tratamiento una formulación de dosis de liberación controlada de acuerdo a cualquiera de las reivindicaciones 1-21. Reivindicación 53: Un conjunto de formas de dosis de liberación controlada, caracterizado porque comprende una pluralidad de formas de dosis de liberación controlada individuales, en donde cada forma de dosis individual comprende una cantidad diferente de dicho compuesto de acuerdo a las reivindicaciones 1, 7 o 17.Claim 1: A controlled release dose formulation, characterized in that it comprises a compound of the formula (1), in which: R1 and R2 are, independently, hydrogen, C1-6 alkyl, phenyl or benzyl; or R1 and R2, taken together, are benzylidene optionally substituted with R3 as defined below or alkylidene of up to 6 carbon atoms; or R1 and R2, taken in conjunction with the carbon atom to which they are attached, form a carbonyl residue or a cycloalkyl group having up to 6 carbon atoms; R3 is hydrogen, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, C1-6 alkyl, C1-6 alkoxy, C7-12 arylalkoxy, C2-6 alkanoyloxy, amino, mono- or di-alkylamino in which each C1-6 alkyl group, C2-6 alkanamide or C1-6 alkanesulfonamido; R4 is hydrogen or C1-6 alkyl; n is one of the integers 0, 1, 2, 3, 4, 5, or 6; Z is hydrogen, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-8 cycloalkyl, C7-15 polycyclic alkyl, phenyl optionally substituted with R3 as defined above, phenoxy, optionally substituted with R3 as defined above, naphthyl optionally substituted with R3 as defined above or naphthyloxy optionally substituted with R3 as defined above, heteroaryl or heteroaryloxy, wherein the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene , furan, pyridine, pyrazine, pyrimidine, indole, indazol imidazole, chromane, coumarin, carbostyryl, quinoline, bencisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R3 as defined above ; or a pharmaceutically acceptable salt thereof. Claim 22: A treatment method for a dopamine system disorder, characterized in that it comprises administering to a patient in need of said treatment a controlled release dose formulation according to any of claims 1-21. Claim 53: A set of controlled release dose forms, characterized in that it comprises a plurality of individual controlled release dose forms, wherein each individual dose form comprises a different amount of said compound according to claims 1, 7 or 17.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51531503P | 2003-10-29 | 2003-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046222A1 true AR046222A1 (en) | 2005-11-30 |
Family
ID=34572826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103986A AR046222A1 (en) | 2003-10-29 | 2004-10-29 | PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION INCLUDING APLINDORE AND ITS DERIVATIVES |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20050095292A1 (en) |
| EP (1) | EP1675583B1 (en) |
| JP (1) | JP5547865B2 (en) |
| KR (1) | KR101409724B1 (en) |
| CN (2) | CN1874767A (en) |
| AR (1) | AR046222A1 (en) |
| AU (1) | AU2004286855B2 (en) |
| BR (1) | BRPI0415953B8 (en) |
| CA (1) | CA2543045C (en) |
| ES (1) | ES2405404T3 (en) |
| GT (1) | GT200400218A (en) |
| IL (1) | IL174958A (en) |
| MX (1) | MXPA06004752A (en) |
| NO (1) | NO20062004L (en) |
| PA (1) | PA8616201A1 (en) |
| PE (1) | PE20050484A1 (en) |
| RU (1) | RU2376988C2 (en) |
| SG (1) | SG147450A1 (en) |
| TW (1) | TW200517106A (en) |
| WO (1) | WO2005044262A1 (en) |
| ZA (1) | ZA200603409B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1874767A (en) | 2003-10-29 | 2006-12-06 | 惠氏公司 | Sustained-release pharmaceutical composition comprising APLINDORE and its derivatives |
| US8858993B2 (en) * | 2005-07-25 | 2014-10-14 | Metrics, Inc. | Coated tablet with zero-order or near zero-order release kinetics |
| AU2006282900B2 (en) * | 2005-08-26 | 2011-11-03 | Bpsi Holdings Llc | Drug compositions containing controlled release hypromellose matrices |
| US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
| RU2554347C2 (en) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Methylhydrofumarate prodrugs, pharmaceutical compositions containing them and methods for using |
| AR074825A1 (en) * | 2008-12-22 | 2011-02-16 | Novartis Ag | DOSAGE REGIME OF AN S1P RECEIVER AGONIST, TREATMENT METHOD AND KIT |
| EP3646870A1 (en) | 2009-07-22 | 2020-05-06 | Puretech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| EP2468264A1 (en) * | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
| MA34897B1 (en) | 2011-01-07 | 2014-02-01 | Novartis Ag | FORMATIONS OF IMMUNOSUPPRESSORS |
| CA2845228C (en) | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| EP2887933A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| WO2015035184A1 (en) | 2013-09-06 | 2015-03-12 | Xenoport, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015123352A1 (en) | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| EA201791455A1 (en) | 2014-12-22 | 2017-12-29 | Кардиора Пти Лтд. | METHOD OF TREATMENT |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| EP3641732A1 (en) | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| JP6983139B2 (en) * | 2017-11-27 | 2021-12-17 | 信越化学工業株式会社 | Compositions for solid formulations, solid formulations and methods for producing them |
| US10980747B2 (en) * | 2017-11-27 | 2021-04-20 | Shin-Etsu Chemical Co., Ltd. | Composition for solid preparation, solid preparation, and method for producing the same |
| CN111788196A (en) | 2018-01-09 | 2020-10-16 | 配体药物公司 | Acetal compounds and their therapeutic uses |
| EP3856182B1 (en) | 2018-09-28 | 2025-12-24 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation |
| TWI841545B (en) * | 2018-12-12 | 2024-05-11 | 日商田邊三菱製藥股份有限公司 | Gastro-resistant controlled release oral dosage forms |
| CN115710224A (en) * | 2020-06-28 | 2023-02-24 | 海创药业股份有限公司 | A kind of quinoline compound crystal form and preparation method thereof |
| CN116549406B (en) * | 2023-05-23 | 2023-12-19 | 北京丰科睿泰医药科技有限公司 | Trazodone hydrochloride sustained-release tablet |
| US12466883B1 (en) | 2024-05-13 | 2025-11-11 | Lumen Bioscience, Inc. | Leptin compositions and methods of making and using the same to support weight loss and/or maintenance |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2624732B1 (en) * | 1987-12-21 | 1991-02-15 | Synthelabo | SUSTAINED RELEASE PHARMACEUTICAL FORMULATION |
| JP2687448B2 (en) * | 1988-06-22 | 1997-12-08 | 大正製薬株式会社 | Ibuprofen sustained release formulation |
| US5028434A (en) * | 1988-07-21 | 1991-07-02 | Alza Corporation | Method for administering nilvadipine for treating cardiovascular symptoms |
| US4988679A (en) * | 1989-01-03 | 1991-01-29 | Leonard Chavkin | Liquid sustained release composition |
| US5009895A (en) * | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| CA2075057A1 (en) | 1990-03-15 | 1991-09-16 | Pharmacia & Upjohn Company Llc | Therapeutically useful heterocyclic indole compounds |
| JP2600978B2 (en) * | 1990-05-25 | 1997-04-16 | 日産自動車株式会社 | Suspension upper link support structure |
| US5128366A (en) * | 1990-07-05 | 1992-07-07 | Shinogi & Co., Ltd. | Pyrrole derivatives |
| US5168387A (en) * | 1990-12-11 | 1992-12-01 | Central Glass Company, Limited | Variable light transmittance device |
| US5633376A (en) * | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
| JP2829794B2 (en) * | 1991-02-08 | 1998-12-02 | エスエス製薬 株式会社 | Orally administered pranoprofen formulation for sustained release |
| US5126366A (en) | 1991-06-21 | 1992-06-30 | American Home Products Corporation | Aminophenoxyalkyl derivatives of benzodioxan |
| US5166367A (en) | 1991-06-21 | 1992-11-24 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5189171A (en) | 1991-06-21 | 1993-02-23 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| DE4135474A1 (en) * | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-AMINOMETHYL-chromans |
| US5235055A (en) * | 1992-09-02 | 1993-08-10 | American Home Products Corporation | Antipsychotic quinoline derivatives of benzodioxanmethylamine |
| US5245051A (en) * | 1992-09-03 | 1993-09-14 | American Home Products Corporation | Antipsychotic chroman derivatives of benzodioxanmethylamine |
| EP0939135A1 (en) | 1992-12-21 | 1999-09-01 | Duphar International Research B.V | Substantially pure hetero-bicyclic alcohol enantiomers |
| GB9514842D0 (en) | 1995-07-20 | 1995-09-20 | Smithkline Beecham Plc | Novel formulation |
| US5756532A (en) * | 1995-11-06 | 1998-05-26 | American Home Products Corporation | Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives |
| US6126970A (en) * | 1995-12-01 | 2000-10-03 | Janssen Pharmaceutica N.V. | Cisapride sustained release |
| JPH09315969A (en) * | 1996-05-24 | 1997-12-09 | Taiyo Yakuhin Kogyo Kk | Ibudilast-containing sustained release medicinal composition and its production |
| GB9627005D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
| GB9704948D0 (en) * | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
| TW587938B (en) | 1997-03-27 | 2004-05-21 | Akzo Nobel Nv | Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder |
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| ATE431141T1 (en) * | 1999-07-13 | 2009-05-15 | Alpha Res Group Llc | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE |
| PT1235574E (en) * | 1999-12-03 | 2005-05-31 | Polichem Sa | METHODS FOR PREPARING PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERTACAO OF DAILY ALCALOIDS HAVING AN IMPROVED BIODISPONIBILITY AND COMPOSITIONS SO OBTAINED |
| HK1045942A1 (en) | 1999-12-10 | 2002-12-20 | Wyeth | Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| US6350773B1 (en) | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
| US6524618B1 (en) * | 2001-06-12 | 2003-02-25 | Vijai Kumar | Directly compressible extended-release matrix formulation for metformin hydrochloride |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| AR046811A1 (en) * | 2003-09-02 | 2005-12-28 | Imran Ahmed | ORAL DOSAGE FORMS OF ZIPRASIDONE OF SUSTAINED LIBERATION |
| CN1874767A (en) | 2003-10-29 | 2006-12-06 | 惠氏公司 | Sustained-release pharmaceutical composition comprising APLINDORE and its derivatives |
| TW200811182A (en) | 2006-05-25 | 2008-03-01 | Wyeth Corp | Oxindoledioxans, synthesis thereof, and intermediates thereto |
-
2004
- 2004-10-28 CN CNA2004800319308A patent/CN1874767A/en active Pending
- 2004-10-28 PA PA20048616201A patent/PA8616201A1/en unknown
- 2004-10-28 BR BRPI0415953A patent/BRPI0415953B8/en not_active IP Right Cessation
- 2004-10-28 EP EP04818331A patent/EP1675583B1/en not_active Expired - Lifetime
- 2004-10-28 CN CN2011102045501A patent/CN102335116A/en active Pending
- 2004-10-28 US US10/975,254 patent/US20050095292A1/en not_active Abandoned
- 2004-10-28 MX MXPA06004752A patent/MXPA06004752A/en active IP Right Grant
- 2004-10-28 WO PCT/US2004/036013 patent/WO2005044262A1/en not_active Ceased
- 2004-10-28 KR KR1020067008178A patent/KR101409724B1/en not_active Expired - Lifetime
- 2004-10-28 GT GT200400218A patent/GT200400218A/en unknown
- 2004-10-28 PE PE2004001037A patent/PE20050484A1/en not_active Application Discontinuation
- 2004-10-28 ES ES04818331T patent/ES2405404T3/en not_active Expired - Lifetime
- 2004-10-28 SG SG200807793-5A patent/SG147450A1/en unknown
- 2004-10-28 AU AU2004286855A patent/AU2004286855B2/en not_active Ceased
- 2004-10-28 TW TW093132737A patent/TW200517106A/en unknown
- 2004-10-28 RU RU2006118321/15A patent/RU2376988C2/en active
- 2004-10-28 CA CA2543045A patent/CA2543045C/en not_active Expired - Fee Related
- 2004-10-28 JP JP2006538307A patent/JP5547865B2/en not_active Expired - Lifetime
- 2004-10-29 AR ARP040103986A patent/AR046222A1/en unknown
-
2006
- 2006-04-11 IL IL174958A patent/IL174958A/en active IP Right Grant
- 2006-04-28 ZA ZA200603409A patent/ZA200603409B/en unknown
- 2006-05-04 NO NO20062004A patent/NO20062004L/en not_active Application Discontinuation
-
2018
- 2018-03-05 US US15/912,438 patent/US10292966B2/en not_active Expired - Lifetime
- 2018-08-08 US US16/058,769 patent/US10463648B2/en not_active Expired - Lifetime
-
2019
- 2019-11-01 US US16/672,296 patent/US11179369B2/en not_active Expired - Lifetime
-
2022
- 2022-05-27 US US17/827,560 patent/US20230061743A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046222A1 (en) | PHARMACEUTICAL COMPOSITIONS OF SUSTAINED LIBERATION INCLUDING APLINDORE AND ITS DERIVATIVES | |
| AR064155A1 (en) | COMPOSITES OF PHOSPHINOSITIDE-3 KINASE INHIBITORS AND METHODS OF USE | |
| AR056536A1 (en) | COMPOUNDS OF 2-AMINO-5- [4- (DIFLUORMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE AS INHIBITORS OF THE BETA SECRETASE (BACE) | |
| PE20080772A1 (en) | NEW SUBSTITUTE BIPYRIDINE DERIVATIVES AND THEIR USE | |
| BR112015020302B1 (en) | PYRAZOLE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND INTERMEDIATE COMPOUND | |
| EA200800478A1 (en) | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | |
| BRPI0815154B1 (en) | INDOL COMPOUNDS, COMPOSITION, AND METHOD OF PREPARATION THEREOF | |
| AR079327A1 (en) | DERIVATIVES OF 2-AMINO-5,5-DIFLUOR -5,6-DIHIDRO-4H- (1,3) OXAZIN-4-IL) PHENYL) -AMIDA | |
| PE20080671A1 (en) | DERIVATIVES OF 2-ARIL-6-PHENYL-IMIDAZO [1,2-a] PYRIDINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| AR054560A1 (en) | SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| PE20090276A1 (en) | COMPOUNDS DERIVED FROM IMIDAZOQUINOLINE AS MODULATORS OF TLR7 | |
| AR081932A1 (en) | DERIVATIVES OF HETEROARIL IMIDAZOLONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF NEOPLASIC AND AUTOINMUNE DISEASES | |
| AR004284A1 (en) | DERIVATIVES OF AMINOMETIL-2,3,8,9-TETRAHIDRO-7H-1,4-DIOXINO-2,3-E-INDOL-8-ONAS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| AR067845A1 (en) | COMPOUNDS TO TREAT DISORDERS RELATED TO THE MODULATION OF RIANODINE RECEPTORS AND PHARMACEUTICAL COMPOSITION | |
| PE20090297A1 (en) | HETEROARYL-SUBSTITUTED PIRAZOLE DERIVATIVES USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | |
| PE20090290A1 (en) | PYRROLOPYRIDINE DERIVATIVES AS BACE INHIBITORS | |
| AR045143A1 (en) | INDAZOL COMPOUNDS 3,5- DISTRIBUTED, PHARMACEUTICAL COMPOSITIONS AND METHODS TO INTERVENE IN OR INHIBIT THE CELL PROLIFERATION | |
| BR112017004141B1 (en) | Imaging agent and its use | |
| EA201791254A1 (en) | CRYSTAL SOLVATES AND COMPLEXES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLYCYTOL WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT | |
| PE20080403A1 (en) | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | |
| RU2010126105A (en) | Pyridine derivatives substituted by a heterocyclic ring and a phosphonoxymethyl group and containing antifungal agents | |
| PE20091818A1 (en) | POLYSUSTITUTED DERIVATIVES OF 2-ARIL-6-FENYL-IMIDAZO [1,2-a] PYRIDINES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | |
| WO2012057248A1 (en) | Naphthyridine derivative | |
| AR073262A1 (en) | DERIVATIVES OF PIRAZOLO [5, 1-B] OXAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF DISEASES MEDIATIONED BY CRF1 ANTAGONISTS. | |
| AR065531A1 (en) | PIRIMIDINE DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |